Arbutus Biopharma
ABUS
162 hedge funds and large institutions have $365M invested in Arbutus Biopharma in 2025 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 65 increasing their positions, 44 reducing their positions, and 18 closing their positions.
106% more call options, than puts
Call options by funds: $3.27M | Put options by funds: $1.59M
48% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 44
3.29% more ownership
Funds ownership: 58.38% → 61.67% (+3.3%)
3% less funds holding
Funds holding: 167 → 162 (-5)
6% less capital invested
Capital invested by funds: $390M → $365M (-$25.1M)
22% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 18
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.32M |
| 2 |
TSC
Two Seas Capital
Rye,
New York
|
+$3.25M |
| 3 |
Goldman Sachs
New York
|
+$3.2M |
| 4 |
UBS AM
Chicago,
Illinois
|
+$3.18M |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$3.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Stempoint Capital
New York
|
-$1.63M |
| 2 |
RC
Rangeley Capital
New Canaan,
Connecticut
|
-$1.61M |
| 3 |
JP Morgan Chase
New York
|
-$1.5M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$933K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$607K |
ABUS Hedge Fund Activity: Q2 2025 in Review
162 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q2 2025, worth a combined $365M — down 6.4% from $390M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ABUS and 14 opened new positions — a net loss of 4 holders — while 44 trimmed existing stakes and 65 added.
The largest buyer was Adage Capital Partners, adding an estimated $3.32M. The largest seller was Stempoint Capital, exiting entirely with an estimated $1.63M sold.
- 162 institutional investors held Arbutus Biopharma (ABUS) as of Q2 2025, down from 167 in Q1 2025.
- Funds reported $365M of Arbutus Biopharma stock for Q2 2025, down 6.4% quarter-over-quarter.
- 14 funds opened new Arbutus Biopharma positions in Q2 2025 and 18 closed out, a net change of -4 holders.
- The largest Arbutus Biopharma buyer in Q2 2025 was Adage Capital Partners, an estimated $3.32M added.
- The largest Arbutus Biopharma seller in Q2 2025 was Stempoint Capital, an estimated $1.63M sold.
Based on aggregated 13F filings for Q2 2025.